Asia Pacific Central Nervous System Therapeutic Market Size & Outlook
The central nervous system therapeutic market in Asia Pacific is expected to reach a projected revenue of US$ 60,215.3 million by 2033. A compound annual growth rate of 10.1% is expected of Asia Pacific central nervous system therapeutic market from 2026 to 2033.
Biogen Inc, Otsuka Pharmaceutical, Eli Lilly and Co, Merck & Co Inc, AstraZeneca PLC, Novartis AG ADR, Teva Pharmaceutical Industries Ltd, Johnson & Johnson, Pfizer Inc
Other key industry trends
In terms of revenue, Asia Pacific region accounted for 20.5% of the global central nervous system therapeutic market in 2025.
Globally, North America is projected to lead the regional market in terms of revenue in 2033.
Asia Pacific is the fastest growing regional market and is projected to reach USD 60,215.3 million by 2033.
Asia Pacific region is expected to grow at the fastest rate over the forecast period. High prevalence of neurodegenerative diseases, increasing awareness regarding mental health, and improving healthcare infrastructure in the region are anticipated to boost regional market growth.
Developed countries in the Asia Pacific region, such Japan, South Korea, and Australia, have better healthcare policies and established public health policies focused on mental health. Moreover, developing countries in the region are reforming healthcare policies to improve the life of patients living with neurological disorders.
Asia Pacific Central Nervous System Therapeutic Market Outlook
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to Central Nervous System Therapeutic Market Outlook will help companies and investors design strategic landscapes.
Neurodegenerative Diseases was the largest segment with a revenue share of 37.47% in 2025.
Horizon Databook has segmented the Asia Pacific central nervous system therapeutic market based on neurovascular diseases, cns trauma, mental health, neurodegenerative diseases, infectious diseases, cns cancer covering the revenue growth of each sub-segment from 2021 to 2033.
Asia Pacific region is expected to grow at the fastest rate over the forecast period. High prevalence of neurodegenerative diseases, increasing awareness regarding mental health, and improving healthcare infrastructure in the region are anticipated to boost regional market growth.
Developed countries in the Asia Pacific region, such Japan, South Korea, and Australia, have better healthcare policies and established public health policies focused on mental health. Moreover, developing countries in the region are reforming healthcare policies to improve the life of patients living with neurological disorders.
Asia Pacific Central Nervous System Therapeutic Market Disease Outlook (Revenue, USD Million , 2021-2033)
Neurovascular Diseases
CNS Trauma
Mental Health
Neurodegenerative Diseases
Infectious Diseases
CNS Cancer
Others
Asia Pacific Central Nervous System Therapeutic Market Drug Class Outlook (Revenue, USD Million , 2021-2033)
Antidepressants
Antipsychotics
Antiepileptics (AEDs)
Dopaminergic Agents
Neuroprotective Agents
Immunomodulators
Others
Asia Pacific Central Nervous System Therapeutic Market Distribution Channel Outlook (Revenue, USD Million , 2021-2033)
Hospital Pharmacy
Retail Pharmacy
Others
Reasons to subscribe to Central Nervous System Therapeutic Market Outlook databook
Access to comprehensive data: Horizon Databook provides over 1 million market statistics and 20,000+ reports, offering extensive coverage across various industries and regions.
Informed decision making: Subscribers gain insights into market trends, customer preferences, and competitor strategies, empowering informed business decisions.
Cost-Effective solution: It's recognized as the world's most cost-effective market research database, offering high ROI through its vast repository of data and reports.
Customizable reports: Tailored reports and analytics allow companies to drill down into specific markets, demographics, or product segments, adapting to unique business needs.
Strategic advantage: By staying updated with the latest market intelligence, companies can stay ahead of competitors, anticipate industry shifts, and capitalize on emerging opportunities.
Target buyers of Central Nervous System Therapeutic Market Outlook databook
Our clientele includes a mix of Central Nervous System Therapeutic Market Outlook companies, investment firms, advisory firms & academic institutions.
30% of our revenue is generated working with investment firms and helping them identify viable opportunity areas.
Approximately 65% of our revenue is generated working with competitive intelligence & market intelligence teams of market participants (manufacturers, service providers, etc.).
The rest of the revenue is generated working with academic and research not-for-profit institutes. We do our bit of pro-bono by working with these institutions at subsidized rates.
Horizon Databook provides a detailed overview of continent-level data and insights on the Asia Pacific Central Nervous System Therapeutic Market Outlook, including forecasts for subscribers. This continent databook contains high-level insights into Asia Pacific Central Nervous System Therapeutic Market Outlook from 2021 to 2033, including revenue numbers, major trends, and company profiles.
Asia Pacific Central Nervous System Therapeutic Market, 2021-2033 (US$M)